News

FDA opens expanded access to daraxonrasib for metastatic pancreatic cancer, as phase 3 data boost survival and clinics race to manage access hurdles.

FDA extends camizestrant review as ctDNA-guided ESR1 switch sparks debate; new analyses debut at ASCO while Europe advances approval.

Oncologists weigh second-line options after ICI failure in metastatic ccRCC, spotlighting lenvatinib/everolimus, new agents, and ICI rechallenge.

During a live event, Firas El Chaer, MD, highlighted pivotal data informing decision making in frontline polycythemia vera.

In an in-depth interview, Omar Nadeem, MD, explores the promising findings from 20 patients with smoldering myeloma treated with cilta-cel.

"This [TALAPRO-2] analysis represents the first...patient-level analysis to evaluate rPFS–OS correlation for a PARP inhibitor in first-line mCRPC," said Neeraj Agarwal, MD.

Durvalumab plus BCG induction/maintenance showed a tolerable safety profile in BCG-naive NMIBC, according to the phase 3b PATAPSCO study.

Hafnium oxide nanoparticle radioenhancer adds safely to standard chemoradiotherapy in unresectable stage III NSCLC, showing deep responses and promising early efficacy.

During a live event, Amit Mahipal, MD, and participants discussed first-line treatment selection for unresectable or metastatic hepatocellular carcinoma.

The FDA awarded rare pediatric disease and orphan drug designation to the novel small molecule FL118 for osteosarcoma.

Explore how genomic assays guide personalized early-stage ER+/HER2– breast cancer treatment, weighing Oncotype, MammaPrint, menopausal status, and chemotherapy decisions.

The approval of the TROP2-directed ADC datopotamab deruxtecan is supported by results from the phase 3 TROPION-Breast02 trial.

The results strengthen the evidence base for imetelstat's benefit in this high-risk, post-ruxolitinib myelofibrosis population.

A phase 1 trial investigating autologous KMCAR T cells has been initiated in patients with relapsed/refractory multiple myeloma.

“The use of GLP-1 drugs [vs] DPP-4 inhibitors…was associated with a meaningful reduction in cancer progression,” Mark David Orland, MD.

The study is the first randomized, prospective head-to-head comparison of the cognitive effects of two androgen receptor pathway inhibitors.

The ASCO 2026 lung cancer data include results for amivantamab, lazertinib, pumitamig, silevertinib, and sacituzumab tirumotecan.

During a live Case-Based Roundtable event, Neal Ready, MD, dicussed the rationale for adding an anti–CTLA-4 agent to an anti–PD-1/PD-L1 backbone in NSCLC.

Older men with CLL on BTK inhibitors face sharply higher atrial fibrillation risk, shaping drug choice and prompting stronger cardiovascular screening and monitoring.

Preview ASCO 2026 late-breaking cancer trials—from TNBC ADC survival gains to lung, liver, prostate and myeloma readouts shaping care.

During a live event, Thomas Hutson, DO, PharmD, PhD, and participants discussed current best practice with adjuvant IO post-nephrectomy.

Decade-long trial shows continuous ibrutinib delivers durable survival in high-risk or older CLL, with emerging uMRD and manageable cardiac risks.

Patients with high-risk myelodysplastic syndrome received the novel anti-IL1RAP antibody nadunolimab combined with azacitidine.

The sBLA for nogapendekin alfa inbakicept is supported by 36-month follow-up data from cohort B of the QUILT-3.032 trial.

“Combining [lutetium Lu 177 vipivotide tetraxetan] with ADT and ARPI increased the frequency and depth of PSA responses," said Fred Saad, MD.

FDA grants orphan status to CLN‑049, an FLT3xCD3 T‑cell engager in phase 1, for relapsed/refractory patients with AML.

Long-term real-world safety and effectiveness of darbepoetin alfa in MDS-related anemia are consistent with registration trial findings.

A combination regimen targeting LAG-3 and PD-1 did not significantly extend progression-free survival in advanced melanoma vs single-agent pembrolizumab.